Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1982 1
1988 1
1989 1
1993 1
1999 1
2002 1
2005 1
2006 3
2007 2
2010 3
2011 1
2012 1
2014 1
2016 1
2018 2
2022 2
2023 4
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Cold heart.
Dixon V. Dixon V. Nature. 2018 Dec;564(7735):296. doi: 10.1038/d41586-018-07680-8. Nature. 2018. PMID: 30542168 No abstract available.
FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.
Shi MJ, Fontugne J, Moreno-Vega A, Meng XY, Groeneveld C, Dufour F, Kamoun A, Viborg Lindskrog S, Cabel L, Krucker C, Rapinat A, Dunois-Larde C, Lepage ML, Chapeaublanc E, Levrel O, Dixon V, Lebret T, Almeida A, De Reynies A, Rochel N, Dyrskjøt L, Allory Y, Radvanyi F, Bernard-Pierrot I. Shi MJ, et al. Among authors: dixon v. Eur Urol. 2023 Jan;83(1):70-81. doi: 10.1016/j.eururo.2022.09.030. Epub 2022 Oct 21. Eur Urol. 2023. PMID: 36273937 Free article.
Transcriptomic Profiling of Upper Tract Urothelial Carcinoma: Bladder Cancer Consensus Classification Relevance, Molecular Heterogeneity, and Differential Immune Signatures.
Fontugne J, Xylinas E, Krucker C, Dixon V, Groeneveld CS, Pinar U, Califano G, Bucau M, Verine J, Desgrandchamps F, Hermieu JF, Radvanyi F, Allory Y, Masson-Lecomte A. Fontugne J, et al. Among authors: dixon v. Mod Pathol. 2023 Nov;36(11):100300. doi: 10.1016/j.modpat.2023.100300. Epub 2023 Aug 7. Mod Pathol. 2023. PMID: 37558130 Free article.
Epigenomic mapping identifies an enhancer repertoire that regulates cell identity in bladder cancer through distinct transcription factor networks.
Neyret-Kahn H, Fontugne J, Meng XY, Groeneveld CS, Cabel L, Ye T, Guyon E, Krucker C, Dufour F, Chapeaublanc E, Rapinat A, Jeffery D, Tanguy L, Dixon V, Neuzillet Y, Lebret T, Gentien D, Davidson I, Allory Y, Bernard-Pierrot I, Radvanyi F. Neyret-Kahn H, et al. Among authors: dixon v. Oncogene. 2023 May;42(19):1524-1542. doi: 10.1038/s41388-023-02662-1. Epub 2023 Mar 22. Oncogene. 2023. PMID: 36944729 Free PMC article.
Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial.
Groeneveld CS, Pfister C, Culine S, Harter V, Krucker C, Fontugne J, Dixon V, Sirab N, Bernard-Pierrot I, de Reyniès A, Radvanyi F, Allory Y; VESPER trial investigators. Groeneveld CS, et al. Among authors: dixon v. Ann Oncol. 2024 Sep 17:S0923-7534(24)04016-X. doi: 10.1016/j.annonc.2024.09.008. Online ahead of print. Ann Oncol. 2024. PMID: 39299443
Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.
Lang H, Béraud C, Cabel L, Fontugne J, Lassalle M, Krucker C, Dufour F, Groeneveld CS, Dixon V, Meng X, Kamoun A, Chapeaublanc E, De Reynies A, Gamé X, Rischmann P, Bieche I, Masliah-Planchon J, Beaurepere R, Allory Y, Lindner V, Misseri Y, Radvanyi F, Lluel P, Bernard-Pierrot I, Massfelder T. Lang H, et al. Among authors: dixon v. Front Oncol. 2022 Aug 11;12:930731. doi: 10.3389/fonc.2022.930731. eCollection 2022. Front Oncol. 2022. PMID: 36033544 Free PMC article.
28 results